E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Systemic lupus erythematosus (SLE) |
|
E.1.1.1 | Medical condition in easily understood language |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Immune System Diseases [C20] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 21.1 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10042946 |
E.1.2 | Term | Systemic lupus erythematosus rash |
E.1.2 | System Organ Class | 10040785 - Skin and subcutaneous tissue disorders |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 21.1 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10042945 |
E.1.2 | Term | Systemic lupus erythematosus |
E.1.2 | System Organ Class | 10028395 - Musculoskeletal and connective tissue disorders |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 21.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10042948 |
E.1.2 | Term | Systemic lupus erythematosus syndrome aggravated |
E.1.2 | System Organ Class | 10028395 - Musculoskeletal and connective tissue disorders |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 21.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10042947 |
E.1.2 | Term | Systemic lupus erythematosus synd |
E.1.2 | System Organ Class | 10028395 - Musculoskeletal and connective tissue disorders |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10029142 |
E.1.2 | Term | Nephritis systemic lupus erythematosus |
E.1.2 | System Organ Class | 100000004857 |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.1 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10067657 |
E.1.2 | Term | Systemic lupus erythematosus disease activity index increased |
E.1.2 | System Organ Class | 10022891 - Investigations |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10067658 |
E.1.2 | Term | Systemic lupus erythematosus disease activity index decreased |
E.1.2 | System Organ Class | 10022891 - Investigations |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.1 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10067659 |
E.1.2 | Term | Systemic lupus erythematosus disease activity index abnormal |
E.1.2 | System Organ Class | 10022891 - Investigations |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 21.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10080670 |
E.1.2 | Term | Systemic lupus erythematosus reactivation |
E.1.2 | System Organ Class | 10028395 - Musculoskeletal and connective tissue disorders |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10073694 |
E.1.2 | Term | Lupus pleurisy |
E.1.2 | System Organ Class | 10038738 - Respiratory, thoracic and mediastinal disorders |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 21.1 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10040968 |
E.1.2 | Term | SLE arthritis |
E.1.2 | System Organ Class | 10028395 - Musculoskeletal and connective tissue disorders |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To evaluate the safety and tolerability of ALPN-101 compared to placebo in subjects with moderate to severe active SLE
|
|
E.2.2 | Secondary objectives of the trial |
• To evaluate the efficacy of ALPN-101 in subjects with active SLE • To assess the pharmacokinetics (PK) of ALPN-101 in active SLE • To assess the incidence of anti-drug antibodies (ADA) against ALPN-101
|
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
•Written informed consent •Age 18 to 65 •Diagnosis of lupus for ≥ 6 months prior to Screening •Positive anti-nuclear antibodies (ANA) and/or elevated anti-double-stranded DNA (dsDNA) and/or elevated anti-Smith antibody test at Screening •Active lupus at Screening and Baseline, as defined per-protocol and confirmed by the study's medical monitor •Standard lupus medications must be stable prior to Screening •Women must have a PAP smear and known HPV status within 12 months of Day 1 •All participants must use highly effective birth control if they/their partner are capable of becoming pregnant
|
|
E.4 | Principal exclusion criteria |
•Life-threatening or organ system-threatening lupus activity that is anticipated to require increased treatment during the study •Proteinuria consistent with nephrotic syndrome •Active lupus-related neuropsychiatric disease •Drug-induced lupus •Any serious health condition that would place the subject at undue risk from the study or would confound interpretation of safety or efficacy outcomes •Recent or serious ongoing infection; risk or history of serious infection •Receipt of live vaccination within 8 weeks of Day 1, or expected to require live vaccination during the study •Unacceptable Screening laboratory results •History of new, ongoing, or recurrent malignancy ≤ 5 years prior to Day 1, with some exceptions per-protocol •Pregnant or breastfeeding at the time of screening, or plans to become pregnant ≤ 3 months following the last dose of study drug •Prior diagnosis of, or fulfills diagnostic criteria for, another rheumatic disease that overlaps with lupus or another autoimmune or inflammatory disease that may confound clinical assessments or increase subject risk in the study •Diagnosis of, or fulfills diagnostic criteria for, fibromyalgia •Functional class IV lupus •Does not meet protocol washout periods for concomitant medications •Serious lupus disease activity, which warrants immediate immunosuppressive therapy not appropriate for the study or which makes the possibility of receiving placebo or investigational agent an inappropriate risk •Ongoing participation in another therapeutic clinical trial •Known hypersensitivity to ALPN-101, components thereof, or excipients contained in the drug formulation
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
Safety and tolerability will be assessed by evaluating the type, frequency, severity, and seriousness of adverse events, including clinically significant changes in symptoms, physical exam findings, vital signs, laboratory tests (hematology, serum chemistries and coagulation, urinalysis), and electrocardiograms. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
|
E.5.2 | Secondary end point(s) |
Efficacy Endpoints: Efficacy endpoints will be assessed by evaluating disease activity relative to baseline and across treatment groups using the tools and assessments listed below, and derivatives calculated from them (e.g. SLE Responder Index [SRI] -4, -5, -6 response; time to and proportion with flare of SLE; others). -Global Disease Activity Assessment Tools: • British Isles Lupus Assessment Group index (BILAG) 2004 • Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K); SLEDAI-2K 30-Day (SLEDAI-2K 30) • Physician’s Global Assessment of SLE Disease Activity (PhGA) -Organ-Specific Disease Activity Assessment Tools: • Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI), with photography when appropriate • Swollen Joint Count-28 (SJC-28) • Tender Joint Count-28 (TJC-28) • Estimated glomerular filtration rate (eGFR) • Proteinuria assessed as urine protein to creatinine ratio (UPCR), • Urinary sediment analysis for hematuria, pyuria, and red cell casts -Patient Reported Outcomes and Quality of Life Assessment tools: • Patient’s Global Assessment of Disease Activity (PtGA) • Short Form-36 (SF-36) health survey • Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) (13-Item) -Clinical Biomarkers of SLE Activity: • High-sensitivity C-reactive protein (hsCRP) • Complement levels: C3, C4, CH50 • Anti-dsDNA antibodies -Corticosteroids: • Dose of oral and parenteral corticosteroids
Pharmacokinetic Endpoints: Serum concentrations of ALPN-101 will be measured. Pharmacokinetic endpoints include estimates of maximum concentration (Cmax), area under the concentration-time curve (AUC), and trough concentration (Ctrough) at the end of dosing intervals.
Immunogenicity Endpoints: The presence and titer of ADA against ALPN-101 will be assessed at Baseline (prior to study drug administration on Day 1) and at intervals throughout the study. Samples confirmed positive for ADA may be explored for neutralizing capacity. The relationship between ADA and PK will be analyzed; relationship between ADA and clinical outcomes may be explored.
Pharmacodynamic Endpoints: Blood and urine will be collected at intervals; target saturation by ALPN-101 on circulating lymphocytes will be assessed; plasma, sera and peripheral blood mononuclear cells (PBMCs) will be prepared and may be assessed for biomarkers.
|
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | Yes |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | Yes |
E.6.13.1 | Other scope of the trial description |
|
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 3 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 27 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Germany |
Hungary |
Korea, Republic of |
Poland |
Russian Federation |
Spain |
Taiwan |
United States |
France |
|
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 0 |
E.8.9.1 | In the Member State concerned months | 11 |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial years | 2 |
E.8.9.2 | In all countries concerned by the trial months | 10 |